Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Receivables (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Receivables for 4 consecutive years, with $246.7 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 73.71% to $246.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $246.7 million through Dec 2025, up 73.71% year-over-year, with the annual reading at $246.7 million for FY2025, 73.71% up from the prior year.
  • Receivables hit $246.7 million in Q4 2025 for Axsome Therapeutics, up from $196.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $246.7 million in Q4 2025 to a low of $16.2 million in Q2 2022.
  • Historically, Receivables has averaged $118.2 million across 4 years, with a median of $115.1 million in 2024.
  • Biggest five-year swings in Receivables: surged 413.75% in 2023 and later surged 32.32% in 2024.
  • Year by year, Receivables stood at $46.8 million in 2022, then soared by 129.34% to $107.3 million in 2023, then soared by 32.32% to $142.0 million in 2024, then skyrocketed by 73.71% to $246.7 million in 2025.
  • Business Quant data shows Receivables for AXSM at $246.7 million in Q4 2025, $196.5 million in Q3 2025, and $218.6 million in Q2 2025.